President Trump is scheduled to announce new most-favored-nation drug pricing agreements with nearly a dozen pharmaceutical manufacturers during a 3 p.m. ET Oval Office event on August 31, 2026. This follows the administration’s earlier rollout of the TrumpRx platform, voluntary MFN deals with 17 companies covering most branded drugs, and the January unveiling of the Great Healthcare Plan, which calls on Congress to codify lower prices, redirect ACA subsidies directly to patients, end certain pharmacy benefit manager practices, and increase price transparency. Recent data show prescription drug prices falling 3.9 percent since the start of the term. Traders are focused on the precise policy details, legislative calls, and phrasing the president uses to frame these measures against rising insurance premiums.